Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | CPT2 | P23786 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16882025 | 0.86 | HMGCR (0.58) | HMGCRCHRM1TBXA2RADRA1AFFAR1 | |
| SCHEMBL15259178 | 0.86 | HMGCR (0.58) | HMGCRCHRM1TBXA2RADRA1AFFAR1 | |
| SCHEMBL14864444 | 0.78 | HMGCR (0.54) | HMGCRCHRM1TBXA2RADRA1AFFAR1 | |
| SCHEMBL31267570 | 0.77 | ALDH1A1 (0.45) | ALDH1A1 | |
| SCHEMBL14508457 | 0.76 | HMGCR (0.56) | HMGCRCHRM1TBXA2RADRA1AFFAR1 | |
| SCHEMBL8736083 | 0.73 | HMGCR (0.52) | HMGCRCHRM1TBXA2RADRA1AFFAR1 | |
| SCHEMBL1286788 | 0.72 | HMGCR (0.50) | HMGCRCHRM1TBXA2RADRA1AFFAR1 | |
| SCHEMBL599363 | 0.72 | HMGCR (0.50) | HMGCRCHRM1TBXA2RADRA1AFFAR1 | |
| SCHEMBL18376075 | 0.72 | HMGCR (0.50) | HMGCRCHRM1TBXA2RADRA1AFFAR1 | |
| SCHEMBL15258419 | 0.72 | MVD (0.47) | HMGCRCHRM1TBXA2RADRA1AFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9604925-B2 | Class II HMG-CoA reductase inhibitors and methods of use | PURDUE RESEARCH FOUNDATION (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150239830-A1 | CLASS II HMG-COA REDUCTASE INHIBITORS AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2015-08-27 | — | — | US | disclosed |
| US-9073832-B2 | Class II HMG-COA reductase inhibitors and methods of use | PURDUE RESEARCH FOUNDATION (US) | 2015-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239830-A1 | CLASS II HMG-COA REDUCTASE INHIBITORS AND METHODS OF USE | HMGCR, HMGB2, HMGB3 | HMGCR 1/4885CHRM1 4610/4885TBXA2R 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.